

Amgen Inc.
**Condensed Consolidated Statements of Operations and
Reconciliation of GAAP Earnings to "Adjusted" Earnings**
(In millions, except per share data)
(Unaudited)

	Three Months Ended March 31, 2004			Three Months Ended March 31, 2003		
	GAAP	Adjustments	"Adjusted"	GAAP	Adjustments	"Adjusted"
Revenues:						
Product sales.....	\$ 2,207.8	\$ -	\$ 2,207.8	\$ 1,635.9	\$ -	\$ 1,635.9
Other	135.2	-	135.2	125.3	-	125.3
Total revenues.....	2,343.0	-	2,343.0	1,761.2	-	1,761.2
Operating expenses:						
Cost of sales.....	373.2	(1.7) (1)	371.5	283.3	(4.9) (1)	278.4
Research and development.....	441.3	(8.4) (1)	432.9	351.3	(9.7) (1)	341.6
Selling, general and administrative.....	516.5	(4.1) (1)	512.4	380.5	(4.8) (1)	375.7
Amortization of intangible assets.....	83.9	(83.9) (2)	-	83.9	(83.9) (2)	-
Total operating expenses.....	1,414.9	(98.1)	1,316.8	1,099.0	(103.3)	995.7
Operating income.....	928.1	98.1	1,026.2	662.2	103.3	765.5
Interest and other income (expense), net..	21.1	-	21.1	25.9	-	25.9
Income before income taxes.....	949.2	98.1	1,047.3	688.1	103.3	791.4
Provision for income taxes.....	259.0	36.0 (3)	295.0	194.8	38.7 (3)	233.5
Net income.....	\$ 690.2	\$ 62.1	\$ 752.3	\$ 493.3	\$ 64.6	\$ 557.9
Earnings per share:						
Basic	\$ 0.54		\$ 0.59	\$ 0.38		\$ 0.43
Diluted (4)	\$ 0.52		\$ 0.57	\$ 0.37		\$ 0.42
Shares used in calculation of earnings per share:						
Basic	1,279.4		1,279.4	1,290.5		1,290.5
Diluted (4)	1,332.5		1,332.5	1,349.9		1,349.9

(1) - (4) See explanatory notes

Amgen Inc.
Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

- (1) To exclude the incremental compensation payable to certain Immunex Corporation employees principally under the Immunex Corporation short-term retention plan. The total estimated remaining costs of such retention benefits is approximately \$10 million, pre-tax, and will be incurred through the quarter ending June 30, 2004.
- (2) To exclude the ongoing, non-cash amortization of acquired intangible assets, primarily ENBREL®, related to the Immunex Corporation acquisition. The total annual non-cash charge is currently estimated to be approximately \$340 million, pre-tax.
- (3) To reflect the tax effect of the above adjustments.
- (4) The following tables present the computations for GAAP and "Adjusted" diluted earnings per share computed under the treasury stock and the "if-converted" methods:

	Three Months Ended March 31, 2004		Three Months Ended March 31, 2003	
	GAAP	"Adjusted"	GAAP	"Adjusted"
Income (Numerator):				
Net income for basic EPS	\$ 690.2	\$ 752.3	\$ 493.3	\$ 557.9
Adjustment for interest expense on Convertible Notes, net of tax	5.3	5.3	5.2	5.2
Net income for diluted EPS, after assumed conversion of Convertible Notes	<u>\$ 695.5</u>	<u>\$ 757.6</u>	<u>\$ 498.5</u>	<u>\$ 563.1</u>
Shares (Denominator):				
Weighted-average shares for basic EPS	1,279.4	1,279.4	1,290.5	1,290.5
Effect of Dilutive Securities	18.1	18.1	24.4	24.4
Effect of Convertible Notes, after assumed conversion of Convertible Notes	35.0	35.0	35.0	35.0
Adjusted weighted-average shares for diluted EPS	<u>1,332.5</u>	<u>1,332.5</u>	<u>1,349.9</u>	<u>1,349.9</u>
Diluted earnings per share	<u>\$ 0.52</u>	<u>\$ 0.57</u>	<u>\$ 0.37</u>	<u>\$ 0.42</u>

Amgen Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)

	<u>March 31, 2004</u>	<u>December 31, 2003</u>
Assets		
Current assets:		
Cash and marketable securities.....	\$ 4,509.1	\$ 5,122.9
Trade receivables, net.....	1,195.2	1,007.9
Inventories.....	736.7	712.6
Other current assets.....	494.4	558.8
Total current assets.....	<u>6,935.4</u>	<u>7,402.2</u>
Property, plant, and equipment, net.....	4,086.3	3,799.4
Intangible assets, net.....	4,408.0	4,455.5
Goodwill.....	9,707.0	9,715.9
Other assets.....	842.7	803.5
Total assets.....	<u>\$ 25,979.4</u>	<u>\$ 26,176.5</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities.....	\$ 1,888.5	\$ 2,246.3
Convertible notes.....	<u>2,887.6</u> *	<u>-</u>
Total current liabilities.....	4,776.1	2,246.3
Deferred tax liabilities.....	1,432.0	1,461.6
Long-term debt.....	200.0	3,079.5 *
Stockholders' equity.....	<u>19,571.3</u>	<u>19,389.1</u>
Total liabilities and stockholders' equity.....	<u>\$ 25,979.4</u>	<u>\$ 26,176.5</u>
Shares outstanding.....	1,277.6	1,283.7

* Holders of the Convertible Notes may require the Company to purchase all or a portion of the notes on specific dates as early as March 1, 2005 at the original issuance price plus accrued original issue discount through the purchase date. Accordingly, as of March 31, 2004, the Convertible Notes have been reclassified from long-term debt to current liabilities.

Amgen Inc.
Product Sales Detail by Product and Geographic Region
(In millions)
(Unaudited)

	Three Months Ended	
	March 31,	
	2004	2003
EPOGEN® - U.S.....	\$ 590.0	\$ 547.1
Aranesp® - U.S.	329.6	157.9
Aranesp® - International	213.0	96.9
Neulasta® - U.S.	336.3	252.4
Neulasta® - International	58.4	5.5
NEUPOGEN® - U.S.	172.3	194.0
NEUPOGEN® - International	96.7	90.0
ENBREL® - U.S.	381.7	264.5
ENBREL® - International	15.6	9.5
Other product sales - U.S.	7.8	11.6
Other product sales - International	6.4	6.5
Total product sales	<u>\$ 2,207.8</u>	<u>\$ 1,635.9</u>
U.S.	\$ 1,817.7	\$ 1,427.5
International	<u>390.1</u>	<u>208.4</u>
	<u>\$ 2,207.8</u>	<u>\$ 1,635.9</u>